Blog Posts - Alkermes



Adobe Systems (ADBE) Impressive Numbers, Alkermes (ALKS) Schizophrenia Drug Positive Data

Adobe Systems Inc. (ADBE) Shares of ADBE are trading on different levels, after the company delivered stronger financial results than expected, driven by accelerated adoption of Creative Cloud and Adobe Marketing Cloud. For the second quarter fiscal...
by PennyOmega.com on Jun 18, 2014

(ALKS, CLNO, PWRM, SPSC, KMGB) Stocks in Action by PennyToBuck.com

Alkermes, Inc. (NASDAQ:ALKS) announced the initiation of a phase 1/2 study of ALKS 5461 for treatment-resistant depression (TRD). ALKS 5461 is the combination of ALKS 33, a proprietary opioid modulator, and buprenorphine. TRD, which is also known as...

(ORFG, NHPR, ALKS, AHGP, AFOP) Stock Updates by DrStockPick.com

Orofino Gold Corp. (ORFG) Orofino Gold Corp. has several Gold development properties in Colombia, a current hot spot of gold production in the world markets. Orofino Gold Corp. is a Colombia based gold producer founded as a private company in 2009 by...

GRHU, AVOT, LLY, AMLN, ALKS, - DoubleInStocks.com Stock News!

  GreenHouse Holdings, Inc. (GRHU.OB) GreenHouse is a past performance government contractor supplying the US military with a wide range of products from rapidly deployable and ballistically protected buildings to sustainable, environmentally s...

Amylin, Alkermes Shares Jump as EU Regulators Recommend Diabetes Drug

Amylin, Alkermes Shares Jump as EU Regulators Recommend Diabetes Drug Will this drug be approved in Europe? Read more on The Motley Fool Lilly, Amylin diabetes drug wins EU recommendation LONDON (Reuters) – An experimental diabetes medicine fro...
by Health and Beauty Reviews on Apr 15, 2011

Romagna: la Sòpa inglesa (la "zuppa inglese")

La ricetta in dialetto romagnolo...
by *ieri & oggi in cucina* on Mar 15, 2011

Amylin, Lilly, Alkermes Diabetes Drug Doesn't Match Rival in Head …

Three companies involved in the development of a once-weekly injection of the Type 2 diabetes drug exenatide reported today that the treatment did not provide. diabetes – Google Blog Search...

FDA Approves Avanir and Forest Labs Treatments for PBA and Bacterial Infections

FDA Ends October With Drug Approvals BOSTON (TheStreet) -- U.S. regulators ended October with two drug approvals, clearing an antibiotic from Forest Labs(FRX_) and a first-time treatment for a neurological disorder developed by Avanir Pharmaceutical...
by Biopharma Investor on Oct 31, 2010

Jim Cramer Makes Mistakes Too

Image by Michael McDonough via FlickrJim Cramer apologizes for his mistakes.  Jim Cramer isn't always right on his calls so just take that in mind when you watch Mad Money.  But the guy is entertaining And sometimes he is right and sometimes he is...
by Biopharma Investor on Oct 24, 2010

Down Biotechs, Equates to Foreign Investments

Between Alkermes (ALKS), Exact Sciencees (EXAS), and Human Genome Sciences (HGSI), I'm actually down a few points than I would like to admit.  But these things are typical with the times and I have investments in other foreign markets that actua...
by Biopharma Investor on Oct 21, 2010

Is the FDA going to Approve Anything These Days? As Amylin And Alkermes Tumble I Look At China Biopharma Plays

Image via WikipediaIs the FDA going to approve anything this October? Right now the FDA has rejected an astounding rate of drugs for approval.  I could see the Obesity drugs not getting approved but the overall approval rate is not very good right n...
by Biopharma Investor on Oct 20, 2010

The Short-Seller Who Got Amylin Right

Image via WikipediaNEW YORK (TheStreet) -- Not all investors are shocked and upset about the decision by U.S. regulators to reject Amylin Pharmaceuticals' (AMLN) diabetes drug Bydureon. Short-sellers -- investors who bet that Amylin shares would fall...
by Biopharma Investor on Oct 20, 2010

Alkermes Gains FDA Approval For Vivitrol, Anticipating Oct 22 Approval with Amylin Pharmaceuticals

Image via CrunchBase Again another winning prediction from my FDA calendar for October.  Expect large gains for Alkermes tomorrow.  I wouldn't sell the stock as they have another approval up on Oct. 22nd in conjunction with Amylin and Eli Lilly fo...
by Biopharma Investor on Oct 12, 2010

The Street's FDA Drug Approval Contest: October's FDA Calendar

Here is Ocotber's FDA Calendar. Along with the Calendar I have put my recommendation for each stock. Some you should really be buying, like Alkermes, others you should be shorting, like Arena, Vivus, and Jazz Pharma. The poll has 3 results:...
by Biopharma Investor on Oct 5, 2010

October FDA Calendar: The Street's FDA Drug Approval Contest

Here are Adam's Street consensus on Ocotber's FDA Calendar. He has readers polling on upcoming FDA decision and you can really get a good understanding on stocks you should be buying/call options and stocks you should probably be shorting/put option...
by Biopharma Investor on Oct 4, 2010

Alkermes Gains FDA Recommendation For Vititrol

I expect a huge day tomorrow for Alkermes with the FDA recommendation of Vivitrol.  PFUDA is Oct. 12, 2010.  I expect approval with Vivotrol but you can never be sure with the FDA.  Again big day tomorrow for Alkermes. Wikinvest---Alk...
by Biopharma Investor on Sep 16, 2010


Trending Topics

Close